DNAJB11

Across TCGA pan-cancer cohorts, DNAJB11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DNAJB11 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DNAJB11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJB11 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where DNAJB11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.301	0.752	.001	48	view →
PDAC	OS	Tertile	III,IV	0.583	0.977	.016	6	view →
LSCC	OS	Median	II,III,IV	0.758	0.903	.006	4	view →
HNSC	OS	Median	II,III,IV	0.930	0.992	.016	4	view →
GBM	DFS	Tertile	All	0.506	0.204	.007	4	view →
LUAD	OS	Quartile	III,IV	0.824	1.000	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DNAJB11–CCRCC (DFS)

Open the CCRCC breakdown →